Rezolute Bio
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info

Press Releases

  • News & Events

  • Overview
  • IR Calendar
Mar 29, 2022 7:00am EDT

Rezolute Joins the Rare Disease Company Coalition

Mar 23, 2022 7:00am EDT

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

Feb 22, 2022 7:00am EST

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Feb 09, 2022 4:05pm EST

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

Nov 12, 2021 4:05pm EST

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

Oct 13, 2021 8:10am EDT

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

Oct 12, 2021 4:05pm EDT

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

Sep 22, 2021 4:05pm EDT

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

Sep 15, 2021 4:56pm EDT

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

Sep 09, 2021 4:05pm EDT

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
rezolute logo

©2023 Rezolute, Inc.

Explore

  • Therapeutic Focus
  • For Patients
  • About
  • Join Us
  • Contact Us
  • Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065
+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Investor Relations Contacts

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News & Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info